다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Blood research, v.48 no.3, 2013년, pp.171 - 177
Suh, Cheolwon (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.) , Kim, Won Seog (Division of Hematology) , Kim, Jin Seok (Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.) , Park, Byeong-Bae (Division of Hematology)
AI-Helper
The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequen...
1 Swerdlow SH Campo E Harris NL WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed Lyon, France IARC Press 2008
2 Jaffe ES Harris NL Stein H Isaacson PG Classification of lymphoid neoplasms: the microscope as a tool for disease discovery Blood 2008 112 4384 4399 19029456
3 Shankland KR Armitage JO Hancock BW Non-Hodgkin lymphoma Lancet 2012 380 848 857 22835603
4 Oh SY Ryoo BY Kim WS Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma Ann Hematol 2006 85 781 786 16847665
5 Oh SY Ryoo BY Kim WS Nongastric marginal zone B-cell lymphoma: analysis of 247 cases Am J Hematol 2007 82 446 452 17266060
6 Oh SY Kwon HC Kim WS Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease Eur J Haematol 2007 79 287 291 17692101
7 Oh SY Kwon HC Kim WS Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study Cancer Lett 2007 258 90 97 17936499
8 Oh SY Kim WS Kim SJ Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases Am J Hematol 2009 84 826 829 19890833
9 Oh SY Kim WS Kim JS Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study Int J Hematol 2010 92 510 517 20838958
10 Oh SY Kim WS Kim JS Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study Ann Hematol 2010 89 563 568 20024551
11 Oh SY Kim WS Kim JS Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study Cancer Sci 2010 101 2443 2447 20831770
12 Oh SY Kim WS Kim JS Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study Acta Haematol 2012 127 100 104 22178776
13 Oh SY Suh C Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors Korean J Intern Med 2010 25 227 236 20830217
14 Yhim HY Kang HJ Choi YH Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study BMC Cancer 2010 10 321 20569446
15 Yhim HY Kim JS Kang HJ Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy Int J Cancer 2012 131 235 243 21823120
16 Kim SJ Kang HJ Kim JS Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone Blood 2011 117 1958 1965 21148334
17 Kim YR Kim JS Min YH Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) J Hematol Oncol 2012 5 49 22889180
18 Lee J Suh C Park YH Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study J Clin Oncol 2006 24 612 618 16380410
19 Kim SJ Oh SY Hong JY When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type Ann Oncol 2010 21 1058 1063 19850636
20 Ahn HK Suh C Chuang SS Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis Ann Oncol 2012 23 2703 2707 22547542
21 Kim YR Kim JS Kim SJ Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy J Hematol Oncol 2011 4 34 21843362
22 Kim SJ Moon JH Kim H Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group Leuk Lymphoma 2012 53 1515 1524 22273250
23 Yun J Kim SJ Won JH Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report Leuk Res 2010 34 1175 1179 20206997
24 Kim SJ Choi CW Mun YC Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) BMC Cancer 2011 11 321 21798075
25 Won YW Kwon JH Lee SI Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL) Ann Hematol 2012 91 223 233 21789622
26 Chang MH Kim SJ Kim K Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea Leuk Lymphoma 2009 50 1119 1125 19557632
27 Kang HJ Kim WS Kim SJ Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study Ann Hematol 2012 91 543 551 21922208
28 Oh SY Kim WS Lee DH Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial Invest New Drugs 2010 28 171 177 19421710
29 Kim JE Yoon DH Jang G A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas Korean J Hematol 2012 47 53 59 22479278
30 Yang DH Kim WS Kim SJ Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma Leuk Lymphoma 2012 53 807 811 22035417
31 Sym SJ Lee DH Kang HJ A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma Cancer Chemother Pharmacol 2009 64 27 33 18839172
32 Park BB Kim WS Eom HS Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial Invest New Drugs 2011 29 154 160 19756371
33 Kang HJ Lee SS Kim KM Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) Asia Pac J Clin Oncol 2011 7 136 145 21585693
34 Kang HJ Lee SS Byun BH Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma Cancer Chemother Pharmacol 2013 71 945 953 23370662
35 Kim SJ Kim K Kim BS Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study J Clin Oncol 2009 27 6027 6032 19884539
36 Lee J Suh C Kang HJ Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Ann Oncol 2008 19 2079 2083 18689866
37 Kim SJ Yoon DH Kang HJ Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial Eur J Cancer 2012 48 3223 3231 22770877
38 Kim SJ Kim K Kim BS Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study Ann Oncol 2009 20 390 392 19211502
39 Lee SC Kim SJ Lee DH Kim WS Suh C Won JH Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2010 45 801 802 19767780
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.